Related Experiment Videos
Prevention of neonatal group B streptococcal infection
M B Landon1, J Harger, D McNellis
1Ohio State University College of Medicine, Magee-Women's Hospital, University of Pittsburgh.
Insights
Preventing neonatal group B streptococcal infection requires further research. Current strategies, whether universal screening or risk-based, necessitate large trials to show differences, highlighting the need for better diagnostic tests.
Area of Science:
- Obstetrics and Gynecology
- Neonatal Medicine
- Infectious Disease Prevention
Background:
- The optimal clinical strategy for preventing neonatal group B streptococcal (GBS) infection remains undetermined.
- Group B streptococcal disease poses a significant risk to newborns, necessitating effective prevention methods.
Purpose of the Study:
- To assess the feasibility of a randomized clinical trial comparing two GBS prevention strategies.
- To estimate attack rates for early-onset GBS disease under different prevention programs.
Main Methods:
- The study evaluated two hypothetical prevention programs: universal prenatal screening with selective intrapartum chemoprophylaxis, and selective intrapartum chemoprophylaxis based on clinical risk factors.
- Sample size calculations were performed for a clinical trial to detect differences in attack rates between the two strategies.
Main Results:
- Both hypothetical strategies demonstrated similar, low attack rates for early-onset GBS disease.
- Detecting significant differences between these strategies would require extremely large sample sizes.
Conclusions:
- Current prevention strategies for neonatal group B streptococcal infection require further investigation.
- The development of rapid intrapartum diagnostic tests for GBS carrier status is crucial.
- Healthcare institutions should individualize their approaches to GBS prevention until improved strategies are validated.
Abstract:
The optimal clinical strategy to prevent neonatal group B streptococcal infection has not been established. The Maternal-Fetal Medicine Units Network assessed the feasibility of a randomized clinical trial to compare the effectiveness of two methods of prevention of streptococcal infection. The attack rates of early-onset group B streptococcal disease were estimated for the following: 1) a hypothetical program of universal prenatal screening and selective intrapartum chemoprophylaxis, and 2) a hypothetical program of selective intrapartum chemoprophylaxis based on clinical risk factors. Sample size requirements were calculated for a clinical trial to detect a significant difference in attack rates between the two hypothetical programs. Similar low attack rates using both strategies would require extremely large sample sizes to detect differences between programs. Until a satisfactory, rapid diagnostic test for intrapartum group B streptococcal carrier status is developed and clinical strategies are tested in populations with varying carriage frequencies, institutions will need to individualize their approaches to prevent early-onset neonatal group B streptococcal disease.